TEL AVIV, Israel--(BUSINESS WIRE)--HAGAR, the developer of GWave, the world's first non-invasive continuous glucose monitoring technology that uses RF waves to measure glucose levels in the blood, will present data from two of its completed clinical studies at the upcoming 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) to be held in Barcelona and online from April 27 to 30.
The first study was an extensive proof of concept conducted at the Sheba Medical Center in Tel Aviv, a leading hospital in Israel. In the study, GWave readings highly correlated with reference lab glucose measurements (R2 = 0.924, 95% CI 0.929–0.979; p < 0.0001). This accuracy is comparable to handheld glucose meters and superior to current continuous glucose monitors (CGMs), which detect glucose levels in interstitial fluid under the skin, but outside of the circulating blood. By measuring blood glucose, the GWave technology eliminates the challenges of current CGM devices.
More recently, HAGAR was granted Breakthrough Device Designation by the US Food and Drug Administration (FDA). The Breakthrough Device Designation is intended to speed the development of products aimed at addressing serious conditions with technology that appears to have a high probability of success. The coveted designation strengthens HAGAR’s commitment to delivering innovative technology to improve the world’s most significant chronic diseases, one which affects more than 422 million people, 8.5% of the world’s population.
“Being invited to this prestigious global conference on diabetes is a recognition of the pioneering work HAGAR has been doing to perfect non-invasive testing, which could substantially improve the management and clinical outcomes of this major disease,” said Dr. Alexander Fleming, who will be presenting the clinical data.
ATTD’s showcasing of these study results is an additional affirmation of Gwave’s promise.
Additionally, Taire Rubin, Co-Founder and VP of Business Development at HAGAR, will be joining the stage at a private Goldman Sachs event on April 7th to discuss diabetes monitoring and how to improve patient outcomes with technology. The private event for institutional investors reflects Goldman Sachs’ dedication to innovation within healthcare, with the event entitled “The New Guard: Privates Leading the Disruption in Healthcare.”
HAGAR will be conducting two additional clinical studies to begin early this fall of 2022.
About HAGAR N.I.G.
HAGAR N.I.G. (Noninvasive Glucose monitoring) is the developer of GWave, the world's first non-invasive continuous glucose monitoring technology that uses RF waves to measure glucose levels in the blood. GWave First Generation is a third of the size of a smartphone. The second-generation device will be a sensor that will integrate into a smartwatch which, like the first generation, will seamlessly connect to an app that can easily be shared with a healthcare provider.
For more information, visit: https://www.hagartech.com/
